# Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

> **NCT04542161** · PHASE2 · RECRUITING · sponsor: **Weill Medical College of Cornell University** · enrollment: 95 (estimated)

## Conditions studied

- Chronic Fatigue Syndrome
- Myalgic Encephalomyelitis

## Interventions

- **DRUG:** NAC 900mg/day
- **DRUG:** NAC 3600mg/day
- **DRUG:** NAC 0mg/day (Placebo)

## Key facts

- **NCT ID:** NCT04542161
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-01
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04542161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04542161, "Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04542161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*